Patents by Inventor Kentarou Kumazawa

Kentarou Kumazawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocycle compound, and production process and application thereof
    Patent number: 8193356
    Abstract: The compound of the present invention is a novel compound which has a specific heterocycle skeleton, particularly a pyrazolonaphthyridine or pyrazoloquinoline skeleton having an organic group (e.g., a carbocycle and a heterocycle) bonding through an alkylene group at 3-position and a carbocycle bonding at 5-position and has a phosphodiesterase IV inhibitory activity. At least one of the ring (the carbocycle or the heterocycle) bonding at 3-position of the pyrazolonaphthyridine skeleton and the carbocycle bonding at 5-position may have a halogenated alkyl group and/or a halogenated alkoxy group as a substituent. Such a compound or a salt thereof is useful as a phosphodiesterase IV inhibitor and the like. According to the present invention, a novel compound having a high phosphodiesterase IV inhibitory effect can be provided.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: June 5, 2012
    Assignee: Aska Pharmaceutical Co., Ltd.
    Inventors: Hashime Kanazawa, Tomoji Aotsuka, Kentarou Kumazawa, Kouki Ishitani, Takashi Nose
  • Pyrazolonaphthyridine derivatives
    Publication number: 20100093782
    Abstract: The target is to provide PDE IV inhibitors which have a highly potent anti-asthmatic and/or COPD-prophylactic/therapeutic profile with unexpectedly excellent safety.
    Type: Application
    Filed: September 15, 2009
    Publication date: April 15, 2010
    Inventors: Hashime Kanazawa, Tomoji Aotsuka, Kentarou Kumazawa, Kouki Ishitani, Takashi Nose
  • Pyrazolonaphthyridine derivative
    Patent number: 7608716
    Abstract: The target is to provide PDE IV inhibitors which have a highly potent anti-asthmatic and/or COPD-prophylactic/therapeutic profile with unexpectedly excellent safety.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: October 27, 2009
    Assignee: Aska Pharmaceutical Co., Ltd.
    Inventors: Hashime Kanazawa, Tomoji Aotsuka, Kentarou Kumazawa, Kouki Ishitani, Takashi Nose
  • Heterocycle Compound, and Production Process and Application Thereof
    Publication number: 20090131467
    Abstract: The compound of the present invention is a novel compound which has a specific heterocycle skeleton, particularly a pyrazolonaphthyridine or pyrazoloquinoline skeleton having an organic group (e.g., a carbocycle and a heterocycle) bonding through an alkylene group at 3-position and a carbocycle bonding at 5-position and has a phosphodiesterase IV inhibitory activity. At least one of the ring (the carbocycle or the heterocycle) bonding at 3-position of the pyrazolonaphthyridine skeleton and the carbocycle bonding at 5-position may have a halogenated alkyl group and/or a halogenated alkoxy group as a substituent. Such a compound or a salt thereof is useful as a phosphodiesterase IV inhibitor and the like. According to the present invention, a novel compound having a high phosphodiesterase IV inhibitory effect can be provided.
    Type: Application
    Filed: September 15, 2006
    Publication date: May 21, 2009
    Inventors: Hashime Kanazawa, Tomoji Aotsuka, Kentarou Kumazawa, Kouki Ishitani, Takashi Nose
  • PDE IV inhibitors
    Patent number: 7115623
    Abstract: The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: October 3, 2006
    Assignee: Aska Pharmaceuticals Co., Ltd.
    Inventors: Tomoji Aotsuka, Kentarou Kumazawa, Nagatoshi Wagatsuma, Kouki Ishitani, Takashi Nose
  • Pyrazolonaphthyridine derivative
    Publication number: 20060040972
    Abstract: The target is to provide PDE IV inhibitors which have a highly potent anti-asthmatic and/or COPD-prophylactic/therapeutic profile with unexpectedly excellent safety.
    Type: Application
    Filed: November 5, 2003
    Publication date: February 23, 2006
    Inventors: Hashime Kanazawa, Tomoji Aotsuka, Kentarou Kumazawa, Kouki Ishitani, Takashi Nose
  • Pde IV inhibitors
    Publication number: 20040176365
    Abstract: The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety.
    Type: Application
    Filed: December 11, 2003
    Publication date: September 9, 2004
    Inventors: Tomoji Aotsuka, Kentarou Kumazawa, Nagatoshi Wagatsuma, Kouki Ishitani, Takashi Nose
  • 1,8-naphthyridin-2(1H)-one derivatives
    Patent number: 6642250
    Abstract: The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: November 4, 2003
    Assignee: Grelan Pharmaceutical Co., Ltd.
    Inventors: Tomoji Aotsuka, Kentarou Kumazawa, Nagatoshi Wagatsuma, Kouki Ishitani
  • Novel 1,8-naphthyridin-2(1h)-one derivatives
    Publication number: 20030036651
    Abstract: The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety.
    Type: Application
    Filed: July 11, 2001
    Publication date: February 20, 2003
    Inventors: Tomoji Aotsuka, Kentarou Kumazawa, Nagatoshi Wagatsuma, Kouki Ishitani